The first studies are underway in Spain with a new radiopharmaceutical, 18F-Sodium Fluoride, to be able to diagnose bone cancer.

The Nuclear Medicine Service of the Technological Institute of Sanitary Services of the Oncology Center MD Anderson of Madrid, in collaboration with the PET Technological Institute, is carrying out a study of a new radiopharmaceutical, which allows to reach an image that shows the increase of the flow regional blood and the degree of remodeling of tissues that are diseased.

Radiopharmaceuticals contain a radioactive substance and are used for the diagnosis and treatment of different diseases, such as cancer. They are also called radioactive medicine.

Dr. Jover, a nuclear medicine physician at the Sanitary Services Technological Institute, comments "that the co-registration of the images obtained by 18F-Sodium Fluoride through hybrid machines (medium hydraulic and electrical medium) allows us to characterize the functional activity of the lesions. to provide an accurate anatomical location and thus improve the specificity of the test. " This is an ideal study to evaluate any bone disease.

Currently, there are numerous international studies that have shown that this new radiopharmaceutical has greater sensitivity, is more specific and has a greater predictive value, positive and negative, than the techniques that have been used up to now.

The advantages of 18F-Sodium Fluoride compared to traditional radiopharmaceuticals are:

  • Greater speed when it comes to obtaining images.
  • More rapid presentation of results compared to the traditional method.
  • It favors the work flow.
  • Improves the level of satisfaction of the patient.

Managing Bone Metastases in Prostate Cancer (November 2019).